8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19

      review-article
      , MBBS, MPH-HPM, FWACS 1 , , MD, MBChB, MSc 2 , , PhD, MBBS, MSc 3
      OTO Open
      SAGE Publications
      COVID-19, coronavirus infection, severe acute respiratory syndrome, SARS-CoV-2, anosmia, gustatory loss, olfactory loss

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Loss of smell and taste are considered potential discriminatory symptoms indicating triaging for coronavirus disease 2019 (COVID-19) and early case identification. However, the estimated prevalence essential to guide public health policy varies in published literature. This meta-analysis aimed to estimate prevalence of smell and taste loss among COVID-19 patients.

          Data Sources

          We conducted systematic searches of PubMed, Embase, Web of Science, and Google Scholar databases for studies published on the prevalence of smell and taste loss in COVID-19 patients.

          Review Methods

          Two authors extracted data on study characteristics and the prevalence of smell and taste loss. Random-effects modeling was used to estimate pooled prevalence. Subgroup analysis and meta-regression were conducted to explore potential heterogeneity sources. This study used PRISMA and MOOSE guidelines.

          Results

          Twenty-seven of 32 studies reported a prevalence of loss of smell, taste, or both from a combined sample of 20,451 COVID-19 patients. The estimated global pooled prevalence of loss of smell among 19,424 COVID-19 patients from 27 studies was 48.47% (95% CI, 33.78%-63.29%). Loss of taste was reported in 20 studies and 8001 patients with an estimated pooled prevalence of 41.47% (95% CI, 3.13%-31.03%), while 13 studies that reported combined loss of smell and taste in 5977 COVID-19 patients indicated a pooled prevalence of 35.04% (95% CI, 22.03%-49.26%).

          Conclusions

          The prevalence of smell and taste loss among COVID-19 patients was high globally, and regional differences supported the relevance of these symptoms as important markers. Health workers must consider them as suspicion indices for empirical diagnosis of severe acute respiratory syndrome coronavirus 2 infection.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

            The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

              An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19.
                Bookmark

                Author and article information

                Journal
                OTO Open
                OTO Open
                OPN
                spopn
                OTO Open
                SAGE Publications (Sage CA: Los Angeles, CA )
                2473-974X
                11 September 2020
                Jul-Sep 2020
                : 4
                : 3
                : 2473974X20957975
                Affiliations
                [1 ]Department of Otorhinolaryngology, University of Abuja and University of Abuja Teaching Hospital, Abuja, Nigeria
                [2 ]Department of Otorhinolaryngology, University College Hospital and College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
                [3 ]Institute of Child Health, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
                Author notes
                [*]Titus Sunday Ibekwe, MBBS, MPH-HPM, FWACS, Department of Otorhinolaryngology, University of Abuja Teaching Hospital, Gwagwalada, PMB 228, Abuja, Nigeria. Emails: titus.ibekwe@ 123456uniabuja.edu.ng , ibekwets@ 123456yahoo.com
                Article
                10.1177_2473974X20957975
                10.1177/2473974X20957975
                7488903
                3e0b86ad-0431-4019-8fc5-78c99928cf8c
                © The Authors 2020

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                : 2 July 2020
                : 19 August 2020
                Categories
                Systematic Review/Meta-analysis
                Custom metadata
                July-September 2020
                ts1

                covid-19,coronavirus infection,severe acute respiratory syndrome,sars-cov-2,anosmia,gustatory loss,olfactory loss

                Comments

                Comment on this article